A well-known injectable birth control method is under fire after multiple studies linked it to a specific kind of brain tumor, and now, lawsuits are piling up against the drugmaker. […] The post ...

Currently, a multidistrict litigation against Pfizer (NYSE: PFE) is underway on behalf of women who claim to have developed meningiomas after receiving four or more consecutive injections of ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer (PFE) stock in focus as company faces lawsuits over its alleged failure to warn about brain tumor risks linked to Depo ...

A 30-page federal lawsuit has been filed in the U.S. District Court of the Eastern District of Texas against Eastman Chemical ...

Depo-Provera is a birth control shot that is injected every three months and features a type of progestin hormone called ...

Tevogen ('Tevogen Bio Holdings Inc.” or 'Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

Mass tort coordination could be on the horizon for a collection of Philadelphia lawsuits tying the injectable contraceptive drug Depo-Provera to brain tumors.

Pfizer Inc. failed to convince advisers to the US Food and Drug Administration to support a dramatic expansion in the use of its prostate cancer drug, a setback that could scuttle the company’s ...

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.